Drug companies live by two calendars. One is the financial calendar of results, dividends and guidance. The other is the regulatory calendar, where a single decision can shape a product's prospects for a decade. For GSK (LSE:GSK), one of the largest companies in the …
Cardiovascular disease (CVD) remains the single largest cause of mortality globally, claiming approximately 18 million lives annually and costing healthcare systems hundreds of billions of pounds in emergency hospitalisations and acute interventions. For decades, clinical physicians have relied on traditional risk calculators—measuring cholesterol, blood …
Reckitt (LSE:RKT) has had a year of two halves. The FTSE 100 consumer goods group set a 2026 closing high of 6,512p on 27 February, then slid to a closing low of 4,443p on 2 June. On the morning of Wednesday 7 October, the …
Company calendars are usually set months in advance, long before anyone knows exactly what else will be happening in the market on a given day. This autumn, that has produced an unusual collision. Unilever (LSE:ULVR) is scheduled to publish its third-quarter trading statement on …
GSK published its second-quarter 2026 results in late July. The company headlined the release by saying it had delivered a solid Q2 core results performance and continued momentum.
Hikma, a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector, published its 2026 interim results and half-year financial report over the summer. In its own announcement, the company said it had delivered a solid first-half performance and reiterated its outlook …
Genus, a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector, released its preliminary results for the year to 30 June 2026 on 10 September 2026, followed by an earnings call the same day.
ConvaTec reported first-half revenue of $1,232m, up 4.4% year on year. Organic growth was 5.0% excluding InnovaMatrix, its wound biologics product.
The dividend went ex-dividend on 27 August 2026 and was paid on 18 September. The trust pays dividends twice a year, with a trailing twelve-month dividend equivalent to a yield of about 4.0%.
The August factsheet showed a share price of 1,738.00p and NAV per share of 1,831.00p at the end of the month, a discount of 5.1%. The trust's website put net assets at £347.6m on the same date.